NCT04249167View on ClinicalTrials.gov

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 23, 2020

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
Interventions
DRUG

Atezolizumab

Given IV

PROCEDURE

Cryosurgery

Undergo cryoablation of the primary tumor

DRUG

Nab-paclitaxel

Given IV

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER